Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study.People with type 2 diabetes and obesity who are taking the drugs are also less likely to die ...

Key takeaways: Less than 10% of adults receiving tirzepatide in clinical trials reported a serious adverse event. Gastrointestinal adverse events were common and increased with tirzepatide dosage.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Studies were included if they were clinical- or randomized controlled trials investigating the performance of Tirzepatide against insulin in any of the following outcomes – Body weight, fasting ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

A phase 3 clinical trial of tirzepatide, sold as Mounjaro, has demonstrated that if taken after an initial weight loss brought about by diet and lifestyle changes, the drug can lead to significant ...

Preliminary data from a large Phase 3 clinical trial is offering promising signs for a new anti-obesity drug. Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 ...

The 52-week SURPASS-4 trial (ClinicalTrials.gov: NCT03730662) is part of a phase 3 global clinical development program for tirzepatide, a novel, once-weekly, dual glucose-dependent insulinotropic ...

In real-world cohort, percentage weight reduction at 1 year was 3.6%, 6.8%, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.